• About us
• Contact

Advertisement

Organisation › Details

Novo Ventures

Novo Holdings is recognized as a world-leading life science investor with a focus on creating long-term value. As a life sciences investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. For more information: https://www.novoholdings.dk/ Novo Ventures is a global team of investment professionals that supports Novo Holdings’ investments in private and public opportunities in the life sciences industry. *

 

	Start	2011-05-03 existent
	Group	Novo Group (Group)
	Industry	venture capital
	Industry 2	LIFE SCIENCES
	Person	Nielsen, Jack B. (Novo Capital 202101 formerly 201411 Partner at Novo Ventures)
	Person 2	Lüneborg, Nanna (Forbion 202109– General Partner before Novo Ventures + Apposite Capital + Cancer Research UK)
	Region	Hellerup
	Country	Denmark
	Street	19 Tuborg Havnevej
	City	2900 Hellerup
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«: Hummingbird Bioscience. (5/18/21). "Press Release: Hummingbird Bioscience Raises US$125 Million in Series C Financing". Singapore.
		Record changed: 2024-03-20

Advertisement

More documents for Novo Group (Group)

• [1] Asceneuron S.A.. (7/16/24). "Press Release: Asceneuron Secures $100 Million Series C Financing to Advance Groundbreaking Therapeutics in Neurodegenerative Diseases". Lausanne & San Francisco, CA....
• [2] Myricx Pharma Ltd.. (7/8/24). "Press Release: Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development". London....
• [3] Single Use Support GmbH. (5/15/24). "Press Release: Novo Holdings Acquires Majority Stake in Single Use Support". Kufstein....
• [4] CMS Hasche Sigle. (3/26/24). "Press Release: CMS Advises Sellers of Cardior Pharmaceuticals on Potential Acquisition by Novo Nordisk". Munich....
• [5] Cardior Pharmaceuticals GmbH. (3/25/24). "Press Release: Novo Nordisk to Acquire Cardior Pharmaceuticals and Strengthen Pipeline in Cardiovascular Disease". Bagsværd & Hannover....
• [6] Novo Nordisk A/S. (1/4/24). "Press Release: Novo Nordisk Enters into Research Collaborations with Omega Therapeutics and Cellarity on Novel Treatment Approaches for Cardiometabolic Diseases". Bagsværd, Cambridge, MA & Somerville, MA....
• [7] LimmaTech Biologics AG. (10/9/23). "Press Release: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections". Schlieren....
• [8] Novo Nordisk A/S. (9/25/23). "Press Release: Valo Health and Novo Nordisk to Collaborate to Discover and Develop Novel Treatments for Cardiometabolic Diseases Using Human Data and Artificial Intelligence". Bagsværd & Boston, MA....
• [9] Embark Laboratories ApS. (8/30/23). "Press Release: Novo Nordisk Acquires Embark Biotech, including Its Lead Asset Targeting Obesity and other Cardiometabolic Diseases". Copenhagen....
• [10] Novo Nordisk A/S. (8/10/23). "Press Release: Novo Nordisk to Acquire Inversago Pharma to Develop New Therapies for People Living with Obesity, Diabetes and other Serious Metabolic Diseases". Bagsværd & Montreal....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.